This includes lymphoma and cancers of lung, colon or pancreatic origins.48 This current work provides a basis for hypothesis-driven clinical trials that would explore an optimal CDK2 inhibitor alone or when combined with another centrosome-targeting agent to combat aneuploid cancers. This evidence concerns the gene CDK2 and cancer.